Stay updated with breaking news from Fund Denmark. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Technology readiness levels (TRLs) indicate how close a particular innovation might be to the market, but say nothing about the likelihood people will want the product and be able to integrate it into their everyday lives.
The current COVID-19 vaccines are designed to trigger an antibody response to the SARS-CoV-2 spike protein, which is vulnerable to mutations that could make the vaccine less effective over time. Focusing on the T-cell instead, Penn State researchers partnered with Evaxion Biotech on a study that was the first to demonstrate the effectiveness of an artificial intelligence-generated vaccine in a live viral challenge model. Such a vaccine may provide long-lasting immunity against future emerging variants and could be used as a model for other seasonal viral diseases like the flu.
Evaxion and Pennsylvania State University publish preclinical data validating our AI-based viral vaccine discovery platform COPENHAGEN, Denmark, April 13, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in AI-powered immunotherapies, announces the...
Investegate announcements from Evaxion Biotech, Evaxion and Pennsylvania State University publish preclinical data validating our AI-based viral vaccine discovery platform
COPENHAGEN, Denmark, April 13, 2023 -- Evaxion Biotech A/S , a clinical-stage biotechnology company specializing in AI-powered immunotherapies, announces the successful publication in... | April 13, 2023